Document is current
Any future updates will be listed below
-
Authors
van Boheemen, Laurette https://orcid.org/0000-0003-3168-548X
Turk, Samina
Beers-Tas, Marian van https://orcid.org/0000-0002-4200-2894
Bos, Wouter
Marsman, Diane https://orcid.org/0000-0002-3103-1374
Griep, Ed N
Starmans-Kool, Mirian
Popa, Calin D https://orcid.org/0000-0001-9470-9720
van Sijl, Alper
Boers, Maarten https://orcid.org/0000-0002-6969-283X
Nurmohamed, Michael T https://orcid.org/0000-0002-6274-1934
van Schaardenburg, Dirkjan https://orcid.org/0000-0003-4006-3762
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02603146 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
https://doi.org/10.1136/bmjopen-2022-063650
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial
https://doi.org/10.1136/rmdopen-2021-001591
-
Funding
Funding for this research was provided by:
Dutch Arthritis Society (13-1-501)
- License Information
